Overview

Immune repertoire sequencing market is poised to value USD 136 million in 2022, growing at a CAGR of 7.1% during the forecast period 2022 to 2028.

Immune repertoire describes the sub-types of proteins that the immune system of an organism produces. Six essential protein types make up the immune systems of vertebrates: two immunoglobulin and four T cell receptors. Researchers and scientists can analyse and comprehend diseases caused by adaptive immune systems thanks to immune repertoire sequencing. Immune repertoire sequencing has broad applications in the discovery of biomarkers, the study of infectious diseases, the study of asthma and allergies, and the study of cancer immunotherapy. To increase the efficiency and cost-effectiveness of rational medication development, immune repertoire sequencing is widely used in biomarker discovery. T cell receptor-beta sequencing services are now available through the Center for Commercialization of Cancer Immunotherapy (C3iBiomarker )'s and Diagnostic unit. Immune repertoire sequencing is helpful in locating the specific antigen information contained in lymphocytes and in comprehending the body's defences against intruders. Immune repertoire sequencing is used for a variety of purposes, such as the discovery of biomarkers, cancer immunotherapy, the investigation of allergies and asthma, and the study of infectious diseases. The usage of immune repertoire sequencing is growing as a result of an increase in the number of novel product launches, product development R&D, and cancer patients. The market's growth will be fueled by these elements as well as increasing government backing. Numerous organisations will keep looking for solutions for immune system biomarkers during the projected period in an effort to create new opportunities for the immunological repertoire sequencing market. The market for immune repertoire sequencing is anticipated to develop as a result of rising demand for customised medicine, which analyses a person's genetic profile to inform decisions about the diagnosis, prevention, and treatment of illnesses.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Immune Repertoire Sequencing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Immune Repertoire Sequencing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Prominent players of the market are:

ABVITRO (NOW JUNO THERAPEUTICS), ADAPTIVE BIOTECHNOLOGIES, AGILENT TECHNOLOGIES, ARCHERDX, INC., BGI, ILLUMINA, INC., IREPERTOIRE, INC., OXFORD NANOPORE TECHNOLOGIES, LTD, PACIFIC BIOSCIENCES, Qiagen N.V., Takara Bio Inc., CD Genomics, Roche Holding AG  and Thermo Fisher Scientific

Immune Repertoire Sequencing Market Segmentation: 

By Product

• Instrument
  o NGS
  o PCR
• Assay, Kits and Reagent
  o TCR Kits
    • Human TCR Kits
    • Mouse TCR Kits
  o BCR Kits
    • Human BCR Kits
    • Mouse BCR Kits
• Analytical Software
  o TCR Analysis Solutions
  o BCR Analysis Solutions
  o TCR & BCR Analysis Solutions
• Services
  o Pre-Sequencing Services
  o Sequencing Services
  o Data Analysis Services

By Application

• Biomarker Discovery
• Autoimmune Diseases
• Cancer Immunotherapy
• Infectious Disease Research
• Asthma and Allergy Research
• Vaccine Development
• Immunodeficiency Identification
• Others (If Any)

By End User

• Diagnostic Labs
• Pharmaceutical and Biotech Companies
• Research Institutes
• Others (If Any)

By Region

• North America
• Europe
• Asia-Pacific
• Latin America 
• Middle East and Africa 

Immune Repertoire Sequencing Market Sample Video:

Competitive Landscape:  
•    Tier 1 players- established companies in the market with a major market share  
•    Tier 2 players 
•    Emerging players which are growing rapidly 
•    New Entrants   

FutureWise Takeaways: 
•    Growth prospects  
•    SWOT analysis 
•    Key trends 
•    Key data points affecting market growth  

Objectives of the Study: 
•    To provide with an exhaustive analysis on the immune repertoire sequencing market based on by products, by application, by end users and by region 
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) 
•    To evaluate and forecast micro-markets and the overall market  
•    To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
•    To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions 
•    Profiling of companies to evaluate their market shares, strategies, financials and core competencies  

Flexible Delivery Model

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Immune Repertoire Sequencing Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Immune Repertoire Sequencing Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Immune Repertoire Sequencing Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Immune Repertoire Sequencing Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Instrument 
        7.1.1. NGS
        7.1.2. PCR
   7.2. Assay, Kits and Reagent 
        7.2.1. TCR Kits
               7.2.1.1. Human TCR Kits
               7.2.1.2. Mouse TCR Kits
        7.2.2. BCR Kits
               7.2.2.1. Human BCR Kits
               7.2.2.2. Mouse BCR Kits
   7.3. Analytical Software
        7.3.1. TCR Analysis Solutions
        7.3.2. BCR Analysis Solutions
        7.3.3. TCR & BCR Analysis Solutions
   7.4. Services
        7.4.1. Pre-Sequencing Services
        7.4.2. Sequencing Services
        7.4.3. Data Analysis Services

8. Immune Repertoire Sequencing Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Biomarker Discovery
   8.2. Autoimmune Diseases
   8.3. Cancer Immunotherapy
   8.4. Infectious Disease Research
   8.5. Asthma and Allergy Research
   8.6. Vaccine Development
   8.7. Immunodeficiency Identification
   8.8. Others (If Any)

9. Immune Repertoire Sequencing Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Diagnostic Labs
   9.2. Pharmaceutical and Biotech Companies
   9.3. Research Institutes
   9.4. Others (If Any)

10. North America Immune Repertoire Sequencing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Immune Repertoire Sequencing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Immune Repertoire Sequencing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Immune Repertoire Sequencing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. GCC
          14.2.2. Israel
          14.2.3. South Africa
          14.2.4. Rest of MEA
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    16.1. ABVITRO (NOW JUNO THERAPEUTICS)
          16.1.1. Company Overview
          16.1.2. Product Portfolio
          16.1.3. SWOT Analysis
          16.1.4. Financial Overview
          16.1.5. Strategic Overview
    16.2. ADAPTIVE BIOTECHNOLOGIES
          16.2.1. Company Overview
          16.2.2. Product Portfolio
          16.2.3. SWOT Analysis
          16.2.4. Financial Overview
          16.2.5. Strategic Overview 
    16.3. AGILENT TECHNOLOGIES
          16.3.1. Company Overview
          16.3.2. Product Portfolio
          16.3.3. SWOT Analysis
          16.3.4. Financial Overview
          16.3.5. Strategic Overview
    16.4. ARCHERDX, INC.
          16.4.1. Company Overview
          16.4.2. Product Portfolio
          16.4.3. SWOT Analysis
          16.4.4. Financial Overview
          16.4.5. Strategic Overview
    16.5. BGI
          16.5.1. Company Overview
          16.5.2. Product Portfolio
          16.5.3. SWOT Analysis
          16.5.4. Financial Overview
          16.5.5. Strategic Overview          
    16.6. ILLUMINA, INC.
          16.6.1. Company Overview
          16.6.2. Product Portfolio
          16.6.3. SWOT Analysis
          16.6.4. Financial Overview
          16.6.5. Strategic Overview     
    16.7. IREPERTOIRE, INC.
          16.7.1. Company Overview
          16.7.2. Product Portfolio
          16.7.3. SWOT Analysis
          16.7.4. Financial Overview
          16.7.5. Strategic Overview
    16.8. OXFORD NANOPORE TECHNOLOGIES, LTD
          16.8.1. Company Overview
          16.8.2. Product Portfolio
          16.8.3. SWOT Analysis
          16.8.4. Financial Overview
          16.8.5. Strategic Overview 
    16.9. PACIFIC BIOSCIENCES
          16.9.1. Company Overview
          16.9.2. Product Portfolio
          16.9.3. SWOT Analysis
          16.9.4. Financial Overview
          16.9.5. Strategic Overview
    16.10.Qiagen N.V.
          16.10.1. Company Overview
          16.10.2. Product Portfolio
          16.10.3. SWOT Analysis
          16.10.4. Financial Overview
          16.10.5. Strategic Overview
    16.11.Takara Bio Inc.
          16.11.1. Company Overview
          16.11.2. Product Portfolio
          16.11.3. SWOT Analysis
          16.11.4. Financial Overview
          16.11.5. Strategic Overview          
    16.12.Thermo Fisher Scientific
          16.12.1. Company Overview
          16.12.2. Product Portfolio
          16.12.3. SWOT Analysis
          16.12.4. Financial Overview
          16.12.5. Strategic Overview      
    16.13.CD Genomics
          16.13.1. Company Overview
          16.13.2. Product Portfolio
          16.13.3. SWOT Analysis
          16.13.4. Financial Overview
          16.13.5. Strategic Overview
    16.14.Roche Holding AG
          16.14.1. Company Overview
          16.14.2. Product Portfolio
          16.14.3. SWOT Analysis
          16.14.4. Financial Overview
          16.14.5. Strategic Overview

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the regulations initiated by healthcare administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client
 

Tables

Figures